Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20414 | 1.00 | TTR (0.56) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL1321264 | 0.84 | NR1H4 (0.41) | TTRAPPPTPN1EPHX2KDM4E | |
| SCHEMBL1321266 | 0.84 | NR1H4 (0.41) | TTRAPPPTPN1EPHX2KDM4E | |
| SCHEMBL31560386 | 0.84 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL6960203 | 0.84 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL6960198 | 0.84 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL21010822 | 0.83 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL19504285 | 0.82 | EPHX2 (0.68) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL14926722 | 0.81 | TTR (0.59) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2085779 | 0.81 | TTR (0.73) | TTRAPPPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038607-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-02-07 | — | — | US | disclosed |
| US-10130617-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-11-20 | — | — | US | disclosed |
| US-20170326115-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | US | disclosed |
| EP-3004090-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| US-9616050-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-04-11 | — | — | US | disclosed |
| US-20160136140-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-05-19 | — | — | US | disclosed |
| EP-3004090-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2016-04-13 | — | — | EP | disclosed |
| US-9155727-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-20140357661-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-12-04 | — | — | US | disclosed |
| WO-2014191726-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-12-04 | — | — | WO | disclosed |
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2609078-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | TTR 4300/4885APP 3860/4885PTPN1 4014/4885 |
| US-10130617-B2 | Chemical compounds | MKI67, RB1, CCNI | TTR 2241/4885APP 2704/4885PTPN1 1799/4885 |
| US-20190038607-A1 | CHEMICAL COMPOUNDS | MKI67, RB1, CCNI | TTR 2241/4885APP 2704/4885PTPN1 1799/4885 |
| US-20140357661-A1 | CHEMICAL COMPOUNDS | MKI67, RB1, CCNI | TTR 2411/4885APP 2806/4885PTPN1 1736/4885 |
| US-20170326115-A1 | CHEMICAL COMPOUNDS | MKI67, RB1, CCNI | TTR 2241/4885APP 2704/4885PTPN1 1799/4885 |
| US-20160136140-A1 | Chemical Compounds | MKI67, RB1, CCNI | TTR 2241/4885APP 2704/4885PTPN1 1799/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | TTR 4451/4885APP 3926/4885PTPN1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.